Expert Review of Clinical Immunology最新文献

Mycosis fungoides and IL-4/13 inhibitors: what is known and unmet needs. 蕈样真菌病和IL-4/13抑制剂：已知和未满足的需求。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-17 DOI: 10.1080/1744666X.2025.2507332

Alba Guglielmo, Alessandro Borghi, Natale Schettini, Marcello Perillo, Monica Corazza, Bianca Maria Piraccini, Alessandro Pileri

{"title":"Mycosis fungoides and IL-4/13 inhibitors: what is known and unmet needs.","authors":"Alba Guglielmo, Alessandro Borghi, Natale Schettini, Marcello Perillo, Monica Corazza, Bianca Maria Piraccini, Alessandro Pileri","doi":"10.1080/1744666X.2025.2507332","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2507332","url":null,"abstract":"Introduction: Dupilumab is a monoclonal antibody that inhibits the IL-4 receptor alpha, preventing the binding of IL-4 and IL-13 and the subsequent signal transduction. Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common form of cutaneous T-cell lymphoma (CTCL). Several cases of MF have been reported following the initiation of dupilumab in patients previously diagnosed with atopic dermatitis.Areas covered: This article is a narrative review of the current state of knowledge regarding the correlation between dupilumab and the development of CTCL. Clinical studies on this topic are reviewed, with a particular focus on the pathogenetic theories proposed to date. Finally, we present a new theory, previously undescribed, regarding the potential role of the cytokine microenvironment in triggering CTCL in patients treated with dupilumab.Expert opinion: Dupilumab could unmask CTCLs by inhibiting IL-4. In fact, a recent study observed that IL-4 plays a key role in maintaining the 'equilibrium phase' between tumor and microenvironment cells. Disruption of this balance could promote the escape of tumor cells and lead to the unmasking of CTCLs.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-7"},"PeriodicalIF":3.9,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between inactivated COVID-19 vaccine and semen quality among males recovered from omicron infection: a retrospective cohort study. COVID-19灭活疫苗与组粒感染后恢复男性精液质量的关系：一项回顾性队列研究

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-15 DOI: 10.1080/1744666X.2025.2507329

Yunlong Li, Yinxia Su, Yangchang Zhang, Zihao Guo, Zhaoyun Chen, Hui Li, Chunyang Zhang, Qiaoge Chi, Yang Ge, Mohammad Javanbakht, Salihu S Musa, Shengzhi Sun, Naijun Tang, Kai Wang, Kailu Wang, Shi Zhao

{"title":"Association between inactivated COVID-19 vaccine and semen quality among males recovered from omicron infection: a retrospective cohort study.","authors":"Yunlong Li, Yinxia Su, Yangchang Zhang, Zihao Guo, Zhaoyun Chen, Hui Li, Chunyang Zhang, Qiaoge Chi, Yang Ge, Mohammad Javanbakht, Salihu S Musa, Shengzhi Sun, Naijun Tang, Kai Wang, Kailu Wang, Shi Zhao","doi":"10.1080/1744666X.2025.2507329","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2507329","url":null,"abstract":"Background: The protective effects of inactivated COVID-19 vaccines against SARS-CoV-2-associated semen impairment remain underexplored. We investigated associations between BBIBP-CorV vaccination and the semen quality in males recovering from SARS-CoV-2 infection.Research design and methods: This single-center retrospective cohort study included 1,496 males recovering from SARS-CoV-2 infection at a tertiary hospital in Urumqi, China (February-May 2023). Participants were categorized into long-term and short-term effects groups based on the interval between semen collection and their most recent SARS-CoV-2 infection. The study assessed the association between the different doses of BBIBP-CorV vaccination and semen quality in both groups.Results: A total of 1496 participants were recruited for the short-term (n = 307) and long-term effect groups (n = 1189). Participants had a median age of 32 (IQR: 30, 35). Compared to unvaccinated controls, 2-dose and 3-dose recipients showed reduced short-term semen quality impairment risks, with adjusted RR of 0.945 (95% CI 0.918, 0.973) and 0.965 (95% CI 0.937, 0.993), respectively. No significant results were found for long-term effect groups.Conclusion: Inactivated COVID-19 vaccination may protect against semen quality impairment among males recovering from SARS-CoV-2 Omicron infection within 90 days, especially in terms of semen volume and sperm progressive motility.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Full consideration of the pollen exposure effect in clinical trial design for pollen-induced allergic rhinitis. 花粉性变应性鼻炎临床试验设计应充分考虑花粉暴露效应。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-14 DOI: 10.1080/1744666X.2025.2504987

Dandan Fang, Xu Zhang, Jingyun Li, Luo Zhang, Yuan Zhang

{"title":"Full consideration of the pollen exposure effect in clinical trial design for pollen-induced allergic rhinitis.","authors":"Dandan Fang, Xu Zhang, Jingyun Li, Luo Zhang, Yuan Zhang","doi":"10.1080/1744666X.2025.2504987","DOIUrl":"10.1080/1744666X.2025.2504987","url":null,"abstract":"Introduction: Allergic rhinitis (AR) is global health concern with an increasing prevalence. Among them, pollen-induced AR (PIAR) exhibits more severe and intense symptoms, decreased quality of life, prominent local inflammation, and is thus more challenging to control. Due to the difficulties in disease control, in recent years, an increasing number of treatment methods, including pharmacotherapy, allergen-specific immunotherapy, and newly developed biologics, have focused on PIAR. It has been shown that the pollen exposure has a significant impact on the symptoms of PIAR and the efficacy of intervention. From this perspective, clinical trials for PIAR need to take full account of pollen exposure, especially when assessing efficacy.Areas covered: This review summarized the effect of pollen exposure on PIAR, including immune responses, symptoms and clinic visits. Current definitions for the pollen season (PS) and the peak pollen season (PPS) are discussed. Based on the previous PIAR-related clinical studies and the available recommendations for clinical trial design, a detailed account of trial protocols which fully considered pollen exposure is provided.Expert opinion: Pollen exposure has a significant impact on PIAR. With fully considering the pollen exposure in the clinical trial design for PIAR, future protocols for PIAR-related studies may be more objective and better harmonized and, therefore, comparable.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-13"},"PeriodicalIF":3.9,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases. 依加替莫德在多种免疫球蛋白g介导的自身免疫性疾病的全球临床试验中的安全性

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-13 DOI: 10.1080/1744666X.2025.2497840

Kelly G Gwathmey, Catherine M Broome, Matthias Goebeler, Hiroyuki Murai, Zsuzsanna Bata-Csörgo, Adrian C Newland, Jeffrey A Allen, Yoshitaka Miyakawa, Peter Ulrichts, Luc Truyen, Jana Podhorna, Rene Kerstens, Sophie Steeland, Jon Beauchamp, Jeffrey T Guptill, James F Howard

{"title":"Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.","authors":"Kelly G Gwathmey, Catherine M Broome, Matthias Goebeler, Hiroyuki Murai, Zsuzsanna Bata-Csörgo, Adrian C Newland, Jeffrey A Allen, Yoshitaka Miyakawa, Peter Ulrichts, Luc Truyen, Jana Podhorna, Rene Kerstens, Sophie Steeland, Jon Beauchamp, Jeffrey T Guptill, James F Howard","doi":"10.1080/1744666X.2025.2497840","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2497840","url":null,"abstract":"Background: Efgartigimod is approved in multiple regions for the treatment of gMG, ITP, and CIDP, and is being evaluated in multiple IgG-mediated autoimmune diseases. Here, we report the long-term safety profiles of efgartigimod IV and PH20 SC across different dosing regimens and diseases where efgartigimod has received regulatory approval.Research design and methods: Efgartigimod safety was assessed across dosing regimens and administration routes in Phase 2, placebo-controlled Phase 3, and OLE studies in participants with gMG, ITP, and CIDP. Analyses were performed on all participants who received ≥ 1 dose or partial dose of efgartigimod or placebo. Data from efgartigimod-treated participants were pooled per disease. Event rates were calculated as events per PYFU.Results: Pooled data included 715 participants representing > 850 PYFU. In efgartigimod-treated participants, most TEAEs were mild-to-moderate in severity, with consistently low event rates for TEAE-related treatment discontinuation (range: 0.05-0.47). Severe and serious infection rates were comparable between placebo- and efgartigimod-treated participants. Rates of TEAEs, severe and serious infections, and treatment discontinuation did not increase with prolonged efgartigimod exposure. Efgartigimod did not reduce albumin or increase LDL cholesterol levels.Conclusions: Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-12"},"PeriodicalIF":3.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NF-κB pathway variants in Iranian patients with inborn errors of immunity. 伊朗先天性免疫缺陷患者NF-κB通路变异

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-09 DOI: 10.1080/1744666X.2025.2500608

Nazanin Fathi, Hassan Abolhassani, Fereshte Salami, Tannaz Moeini Shad, Samaneh Delavari, Reza Yazdani, Arash Kalantari, Sareh Sadat Ebrahimi, Nasrin Beniafard, Seyed Alireza Mahdaviani, Nima Rezaei

{"title":"NF-κB pathway variants in Iranian patients with inborn errors of immunity.","authors":"Nazanin Fathi, Hassan Abolhassani, Fereshte Salami, Tannaz Moeini Shad, Samaneh Delavari, Reza Yazdani, Arash Kalantari, Sareh Sadat Ebrahimi, Nasrin Beniafard, Seyed Alireza Mahdaviani, Nima Rezaei","doi":"10.1080/1744666X.2025.2500608","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2500608","url":null,"abstract":"Background: Clinical and immunological manifestations associated with genetic alterations are crucial for understanding inborn errors of immunity (IEI). This study aims to characterize the clinical and immunological profiles and provide the molecular features of IEI patients from the Iranian population with IEI who harbor rare variants in the nuclear factor kappa B (NF-κB) pathway.Research design and methods: Peripheral blood mononuclear cells (PBMCs) were used for immunophenotyping of B and T lymphocyte subsets via flow cytometry and for assessing T cell proliferation. Immunoblotting was performed to evaluate the expression levels of NF-κB proteins.Results: This multi-center study enrolled 16 patients with mutations in the NFKB1, NFKB2, IKBKB, and IKBKG genes. NFKB1 and NFKB2 mutations were heterozygous, while IKBKB mutations were homozygous, and the IKBKG mutation was hemizygous. Patients exhibited hypogammaglobulinemia and switched memory B cell abnormalities. Immunoblotting revealed decreased NF-κB1 protein expression in most cases. Similarly, NFKB2 mutations led to lower protein expression in unstimulated PBMCs, with mild to strong reductions after stimulation, though some cases showed no significant changes.Conclusions: This study identifies novel IEI cases associated with NF-κB pathway defects. Further comprehensive evaluation and functional analysis of these mutations are warranted to confirm their impact on disease manifestation.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-15"},"PeriodicalIF":3.9,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re-envisioning clinical trial design in systemic sclerosis. 系统性硬化症临床试验设计的再设想。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-08 DOI: 10.1080/1744666X.2025.2500612

Elizabeth R Volkmann, Donald P Tashkin, Vanessa Smith

{"title":"Re-envisioning clinical trial design in systemic sclerosis.","authors":"Elizabeth R Volkmann, Donald P Tashkin, Vanessa Smith","doi":"10.1080/1744666X.2025.2500612","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2500612","url":null,"abstract":"Introduction: Systemic sclerosis (SSc) is a progressive autoimmune rheumatic disease with high morbidity and mortality and few effective treatment options. Increased biopharmaceutical investment in therapeutic development for rare diseases has created new opportunities for drug discovery in SSc. However, despite the increased pipeline activity in SSc, success rates remain dismally low.Areas covered: This review describes the current state of therapeutic development in SSc with an in-depth coverage of cohort enrichment strategies, as well as a discussion of relevant ethical and feasibility concerns. This review also highlights lessons learned from phase 3 trials in SSc published within the last 5 years in PubMed, underscoring the impact of background therapy on SSc disease course during the trial period. Emerging clinical trial formats and endpoints are also explored.Expert opinion: The authors present recommendations to innovate clinical trial design in SSc, which integrate evidence from recent clinical trial and observational cohort studies in SSc. With a focus on the use of external control arms, the application of adaptive trial design and the development of global disease activity measures, the authors outline practical and ethical solutions to design precise and efficient trials in SSc with a higher probability of success.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":3.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AQP9 weakens the cytotoxicity of CD8⁺ T cells in colon adenocarcinoma by boosting M2 polarization of macrophages under hypoxia conditions. 在缺氧条件下，AQP9通过促进巨噬细胞M2极化，减弱CD8+ T细胞在结肠腺癌中的细胞毒性。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-08 DOI: 10.1080/1744666X.2025.2501718

Jinping Chen, Zongda Cai, Shurong Huang, Yangqiang Wang, Shiyang Zhan, Wei Zheng, Pan Chi

{"title":"AQP9 weakens the cytotoxicity of CD8+ T cells in colon adenocarcinoma by boosting M2 polarization of macrophages under hypoxia conditions.","authors":"Jinping Chen, Zongda Cai, Shurong Huang, Yangqiang Wang, Shiyang Zhan, Wei Zheng, Pan Chi","doi":"10.1080/1744666X.2025.2501718","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2501718","url":null,"abstract":"Background: Colon adenocarcinoma (COAD) is a leading cause of cancer mortality, with Aquaporin 9 (AQP9) implicated in its progression. M2 macrophages in the tumor microenvironment (TME) promote cancer metastasis, but the role of AQP9 on M2 macrophages remains unelucidated.Research design and methods: Using COAD cell lines, AQP9 expression was analyzed via RT-qPCR and Western blot (WB). Hypoxic conditions were simulated to assess HIF-1α and AQP9 interactions through ChIP and dual-luciferase assays. AQP9 knockdown effects on proliferation/migration were tested via colony formation and wound healing. M2 macrophage polarization and CD8+ T cell cytotoxicity were evaluated using flow cytometry, ELISA, and IHC in co-culture systems.Results: AQP9 was upregulated in COAD and correlated with poor prognosis. After AQP9 in COAD cells was knocked down, the abilities of tumor cells to migrate and proliferate were dampened. Hypoxia upregulated HIF-1α, which transcriptionally activated AQP9. Knocking down AQP9 repressed the M2 polarization of macrophages, thereby reinforcing the cytotoxicity of CD8+ T cells. No adverse events were reported in vitro.Conclusion: AQP9 promotes COAD progression by driving HIF-1α-mediated M2 polarization, impairing CD8+ T cell function. Key limitations include the lack of in vivo validation and clinical cohort analysis.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-12"},"PeriodicalIF":3.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Induction of aquaporins by plasma of patients with systemic lupus erythematosus. 系统性红斑狼疮患者血浆对水通道蛋白的诱导作用。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-06 DOI: 10.1080/1744666X.2025.2497841

Hussein Baharlooi, Samaneh Enayati, Nooshin Ahmadzadeh, Elham Madreseh, Seyedeh Tahereh Faezi, Majid Alikhani, Ahmadreza Jamshidi, Mahdi Mahmoudi, Elham Farhadi

{"title":"Induction of aquaporins by plasma of patients with systemic lupus erythematosus.","authors":"Hussein Baharlooi, Samaneh Enayati, Nooshin Ahmadzadeh, Elham Madreseh, Seyedeh Tahereh Faezi, Majid Alikhani, Ahmadreza Jamshidi, Mahdi Mahmoudi, Elham Farhadi","doi":"10.1080/1744666X.2025.2497841","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2497841","url":null,"abstract":"Background: Systemic lupus erythematosus is a chronic, multisystemic, inflammatory disease. Aquaporins, a group of transmembrane channels, are known to help prime immune cells and their migration. In this study, a qRT-PCR analysis was performed to identify aquaporins whose expression in SLE patients was associated with the inflammatory profile of B cells.Methods: A stable and healthy line of B cells was cultured and subjected to plasma obtained from SLE patients or healthy individuals for 1 week. Subsequently, gene expression was assessed using real-time PCR.Results: The findings showed that B cells treated with SLE plasma had different expression profiles of inflammatory genes, including TNF-α, IFN-γ, CD40, TNFSF13B, and TNFRSF13C. The study also revealed abnormal expression patterns of aquaporins (AQP3, AQP6, AQP8, and AQP9) in the SLE-treated group. Among the genes, AQP3, AQP6, AQP8, AQP9, and AQP11 were differently correlated with the inflammatory phenotype of B cells. These genes may play a role in the pathogenesis of SLE by affecting B cell proliferation, regulation, inflammation, and cytokine processing.Conclusions: The findings suggest that plasma of SLE patients can induce the inflammatory phenotype of B lymphocytes and the expression of key aquaporin genes, which could impact the development of SLE.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-8"},"PeriodicalIF":3.9,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovative surgical approaches for chronic rhinitis: nasal neurectomy mechanisms, techniques, and clinical outcomes. 慢性鼻炎的创新手术方法：鼻神经切除术机制、技术和临床结果。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-04 DOI: 10.1080/1744666X.2025.2500610

Zengxiao Zhang, Hongzheng Wei, Chengshuo Wang, Luo Zhang, Yuan Zhang

{"title":"Innovative surgical approaches for chronic rhinitis: nasal neurectomy mechanisms, techniques, and clinical outcomes.","authors":"Zengxiao Zhang, Hongzheng Wei, Chengshuo Wang, Luo Zhang, Yuan Zhang","doi":"10.1080/1744666X.2025.2500610","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2500610","url":null,"abstract":"Introduction: Chronic rhinitis (CR) represents a prevalent, persistent inflammatory condition of the nasal mucosa, substantially impacting patients' quality of life. Despite standard pharmacotherapy, many patients with refractory symptoms do not achieve adequate relief, highlighting the need for alternative interventions such as nasal neurectomy.Areas covered: Literature was reviewed on the PubMed, EMBASE, and Web of Science databases published from March 1961 to April 2025. Our review discusses the underlying mechanisms, surgical techniques, and clinical outcomes of different nasal neurectomy approaches, including vidian neurectomy, vidian-branch neurectomy, and anterior ethmoidal neurectomy, as well as recent advancements in endoscopic and minimally invasive methods.Expert opinion: Nasal neurectomy presents a promising alternative for managing refractory CR by directly targeting the neuro-immune pathways that drive symptoms. Understanding the mechanisms, techniques, and clinical outcomes in nasal neurectomy will not only advance our insight into CR pathophysiology but also guide the development of refined, patient-specific surgical strategies for optimal outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":3.9,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Host immune response to respiratory syncytial virus infection and its contribution to protection and susceptibility in adults: a systematic literature review. 成人呼吸道合胞病毒感染的宿主免疫反应及其对保护和易感性的贡献：系统的文献综述。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2025-05-02 DOI: 10.1080/1744666X.2025.2494658

Agnes Chaumont, Alison Martin, Johan Flamaing, Dexter J Wiseman, Corinne Vandermeulen, Erik Jongert, Timothy Mark Doherty, Philippe Buchy, Steven M Varga, Lucile Warter

{"title":"Host immune response to respiratory syncytial virus infection and its contribution to protection and susceptibility in adults: a systematic literature review.","authors":"Agnes Chaumont, Alison Martin, Johan Flamaing, Dexter J Wiseman, Corinne Vandermeulen, Erik Jongert, Timothy Mark Doherty, Philippe Buchy, Steven M Varga, Lucile Warter","doi":"10.1080/1744666X.2025.2494658","DOIUrl":"https://doi.org/10.1080/1744666X.2025.2494658","url":null,"abstract":"Introduction: Respiratory syncytial virus (RSV) is an important pathogen in infants, children, older adults, and those with comorbidities. Mechanisms involving viral proteins appear to underlie the ability of RSV to evade and modulate host immunity. We aimed to understand virus- and host-dependent factors regulating the development and severity of RSV infection, as related to the prevention and treatment of RSV-associated disease in adults, through a systematic literature review (SLR).Methods: An SLR was conducted to identify immune mechanisms involved in the protective response to RSV infection in adults, and responses that may contribute to the development of severe disease. Concurrent searches (MEDLINE/Embase) using embase.com identified relevant papers published between 1990 and 19 April 2023.Results: Of 1813 records identified, 113 were selected for review. Inclusion criteria were based on relevant patient populations, outcomes, and study methodologies. RSV is common, recurrent, and associated with high morbidity and mortality in older adults and people with underlying chronic diseases. Immune responses differ between younger and older adults. The approval of effective vaccines may protect older individuals from symptomatic RSV infection.Conclusions: We established the complexities of RSV immune response, but further research is required to fully understand anti-RSV immunology.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-16"},"PeriodicalIF":3.9,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0